AstraZeneca’s Saruparib Study: Key Insights for Investors

AstraZeneca ((AZN)), Parexel International ((PRXL)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.

AstraZeneca, in collaboration with Parexel, is conducting a Phase I study titled ‘A Modular Phase I, Open-label Study to Assess the Safety, Pharmacokinetics, and Drug Interaction Potential and Relative Bioavailability of Saruparib in Patients With Advanced Solid Malignancies.’ The study aims to evaluate the safety and pharmacokinetics of saruparib, a drug designed to treat advanced solid tumors, and its interaction with other medications.

The study involves testing saruparib in combination with other drugs like digoxin, furosemide, metformin hydrochloride, and rosuvastatin to understand its drug-drug interaction potential. It also assesses the relative bioavailability of saruparib when administered in different formulations.

This interventional study employs a randomized, crossover design without masking, focusing on understanding the drug’s interaction and bioavailability. Participants are allocated to different treatment cohorts to receive various combinations of saruparib and other drugs.

The study began on March 25, 2025, with primary completion expected soon. The latest update was submitted on August 6, 2025, indicating ongoing recruitment.

For investors, this study’s progress could influence AstraZeneca’s stock performance, as successful results may enhance saruparib’s market potential. The study’s outcome could also impact investor sentiment, given the competitive landscape in oncology treatments.

The study is ongoing, with further details available on the ClinicalTrials portal.